Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - radium (223ra) dichloride, quantity: 6600 kbq - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride; sodium citrate dihydrate - xofigo is indicated for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol hemihydrate, quantity: 1.033 mg (equivalent: estradiol, qty 1 mg); drospirenone, quantity: 2 mg - tablet, film coated - excipient ingredients: povidone; hypromellose; magnesium stearate; lactose monohydrate; purified talc; macrogol 6000; titanium dioxide; pregelatinised maize starch; maize starch; iron oxide red - hormone replacement therapy (hrt) for use in the short-term treatment in postmenopausal women with an intact uterus of the climacteric syndrome caused by deficient endogenous oestrogen production due to natural menopause, hypogonadism, castration or primary ovarian failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; sucrose; water for injections; polysorbate 20 - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd) - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo) - diabetic macular oedema (dme) - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo) - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sucrose; polysorbate 20; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd); - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo); - diabetic macular oedema (dme); - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo); - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone,ethinylestradiol -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 52 mg - drug delivery system, intrauterine - excipient ingredients: dimethylsiloxane/methylvinylsiloxane cross linked elastomer - contraception. treatment of idiopathic menorrhagia. prevention of endometrial hyperplasia during oestrogen replacement therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; levonorgestrel, quantity: 100 microgram - tablet, sugar coated - excipient ingredients: calcium carbonate; maize starch; povidone; glycol montanate; lactose monohydrate; macrogol 6000; magnesium stearate; sucrose; purified talc - microlevlen ed is indicated for the prevention of pregnancy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, sugar coated - excipient ingredients: macrogol 6000; maize starch; purified talc; lactose monohydrate; povidone; glycol montanate; calcium carbonate; sucrose; magnesium stearate - microgynon 20 ed is indicated for the prevention of pregnancy.